Ratings Diaceutics PLC

Equities

DXRX

GB00BJQTGV64

Market Closed - London S.E. 11:35:05 2024-05-03 EDT 5-day change 1st Jan Change
98 GBX -1.51% Intraday chart for Diaceutics PLC -4.85% +12.64%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • Low profitability weakens the company.

Ratings chart - Surperformance

Sector: Business Support Services

1st Jan change Capi. Investor Rating ESG Refinitiv
+12.64% 104M -
-28.43% 2.06B -
+24.23% 1.94B
B-
+8.86% 1.72B -
B-
-4.23% 1.69B -
-16.17% 1.59B
D-
-24.70% 1.37B -
-4.99% 1.2B -
-4.66% 1.05B - -
+119.33% 694M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. DXRX Stock
  4. Ratings Diaceutics PLC